This study also provided further evidence that the combination of the two agents raised the incidence of myocarditis and stated that, compared to anti-CTLA-4 antibody, anti-PD-1/PD-L1 antibody may be more likely to cause ICI-associated myocarditis. Here, CTLA4 is linked to myocarditis.